GMC number: 6054876
Year & location of first qualification: 2002, Nottingham University
Specialty: Rheumatology
Clinical interests: Systemic sclerosis & Raynaud’s phenomenon, Digital vasculopathy in autoimmune rheumatic diseases, Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Arterial Hypertension
Secretary: Pamela Stone
Dr John Pauling BMedSci BMBS FRCP (Rheum) PhD
North Bristol NHS Trust and Honorary Senior Lecturer in the School of Translational Sciences at the University of Bristol
Dr John Pauling is a consultant rheumatologist at North Bristol NHS Trust and Honorary Senior Lecturer in the School of Translational Sciences at the University of Bristol. John was awarded the Arthritis Research Campaign Medal before qualifying from Nottingham University Medical School in 2002. In 2009 he was awarded the Dando fellowship, jointly funded by the Raynaud’s & Scleroderma Association and Royal College of Physicians. His PhD research helped John to develop an interest in outcome measures in systemic sclerosis (SSc) research, particularly in relation to peripheral microvascular dysfunction in scleroderma. He has developed and validated new methods for assessing digital vasculopathy including patient reported outcome instruments and laser-derived methods in Raynaud’s phenomenon (RP) and systemic sclerosis. John is a member of the EULAR Microcirculation study group and has contributed to recent initiatives of the UK Scleroderma Study Group. John has published over 130 peer-reviewed journal articles and several book chapters in the field of peripheral vascular disease and systemic sclerosis (h-index 30). He has presented at multiple international meetings.
Dr John Pauling sits on the executive committee of the Scleroderma Clinical Trials Consortium (SCTC) and leads the SCTC Vascular Working Group that is currently undertaking work to develop novel outcome measures for Raynaud’s phenomenon and digital ulcer disease in systemic sclerosis. He co-chairs the OMERACT systemic sclerosis special interest group. He leads the Raynaud’s taskforce for an NIH initiative to appraise outcome measures suitable for assessment by the FDA when considering clinical trials of SSc-RP. He also co-chairs the SCTC Industry Roundtable bringing together industry representatives and international scleroderma investigators to advance clinical trial design in SSc.